Vol. 8, Issue 2, Part E (2022)

Materials and Methods: This is a prospective, observational study of 100 patients of VKC. All demographic data and clinical features of VKC was observed and recorded. Patients were treated with one of the two treatment options namely Bepotastine besilate 1.5% and Olopatadine hydrochloride ophthalmic solutions. Typical symptoms and signs of VKC namely ocular itching, watering, conjunctival hyperemia, tarsal papillary hyperplasia and limbal involvement including Horner Trantas dots were recorded at baseline and at time of follow up on 7^th day, 15^th and 30^th day using simplified scoring. Safety assessment was also done.

Results: After 4 weeks of drug therapy, patients in both arms showed significant improvement in the symptoms and signs.

Conclusion: VKC is a disease of younger population and having male preponderance. Both Bepotastine besilate 1.5% and Olopatadine hydrochloride 0.1% ophthalmic solutions were effective and safe in reducing the clinical symptoms and signs of VKC. However both the agents lacked efficacy in severe limbal forms of VKC.